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Abstract: 
Background: Indications for surgical pulmonary valve replacement (PVR) after repair of 
tetralogy of Fallot (rTOF) have recently been broadened to include asymptomatic patients. 
Methods and Results: The outcome of PVR in adults after rTOF at a single tertiary centre was 
retrospectively studied. Preoperative cardiopulmonary exercise (CPEX) testing was included. 
Mortality was the primary outcome measure. Two-hundred-and-twenty-one PVRs were 
performed in 220 patients (130 male, median age 32, range 16-64 years). Homografts were used 
in 117, xenografts in 103 and a mechanical valve in 1 case. Early (30-day) mortality was 2%. 
Overall survival was 97% at one year, 96% at 3 years and 92% at 10 years. Survival after PVR in 
the later era (2005-2010;n=156) was significantly better compared to survival in the earlier era 
(1993-2004;n=65), [99% versus 94% at 1 year and 98% versus 92% at 3 years, 
respectively,P=0.019]. Earlier era patients were more symptomatic preoperatively (P=0.036) 
with a lower preoperative peak oxygen consumption (peak V̇O2,P<0.001). Freedom from redo 
surgical or transcatheter PVR was 98% at 5 years, and 96% at 10 years for the whole cohort. 
Peak V̇O2, VE/VCO2 slope and heart rate reserve during CPEX testing predicted risk of early 
mortality when analyzed with logistic regression analysis; peak V̇O2 emerged as the strongest 
predictor amongst them on multivariable analysis (Odds ratio 0.65 per ml/kg/min,P=0.041).  
Conclusions: PVR after rTOF has a low and improving mortality, with low need for re-
intervention. Preoperative cardiopulmonary exercise testing predicts surgical outcome and 
should therefore be included in the routine assessment of these patients. 
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INTRODUCTION  
The outcome for patients with tetralogy of Fallot has dramatically improved since the 
introduction of surgical repair.1,2 Pulmonary regurgitation, a common sequela of repair, may be 
well tolerated for decades; it is known, however, to have long-term detrimental effects, including 
exercise intolerance, progressive right ventricular (RV) dilatation and dysfunction, ventricular 
and atrial tachycardia, congestive heart failure and sudden cardiac death.3,4 Implantation of a 
competent pulmonary valve is commonly undertaken to avoid these adverse clinical outcomes. 
Cardiopulmonary exercise (CPEX) testing to assess objective exercise tolerance has been 
proposed as a potential tool for optimal timing of pulmonary valve replacement (PVR), as 
symptoms are often volunteered late by patients and preceded by impairment in CPEX testing 
results. Indeed, CPEX testing has recently become part of routine medical surveillance of these 
patients in our centre. In other disease settings impaired cardiopulmonary exercise performance 
is associated with a higher perioperative surgical risk,5, 6 but the association between baseline 
peak oxygen uptake and surgical risk has not been explored to date in a large cohort of adults 
with previous repair of tetralogy of Fallot (rTOF) undergoing PVR. 
In this study, we therefore examined contemporary outcomes of rTOF patients 
undergoing surgical PVR in a single, tertiary centre, with particular reference to preoperative 
baseline CPEX testing and its potential prognostic value. 
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PATIENTS AND METHODS 
All rTOF patients who underwent surgical PVR between January 1993 and December 2010 
under the care of the adult congenital heart service at the Royal Brompton Hospital, London, UK 
were included. Patients were identified from our surgical database and their hospital records 
were examined. As this was a retrospective analysis of data collected for routine clinical care, 
individual informed consent was not required (UK National Research Ethics Service guidance). 
The study was locally registered and approved. 
Data recorded included demographics, information on previous surgical palliations and repairs, 
details of the surgical procedure including the type of prosthesis used, preoperative New York 
Heart Association (NYHA) class, QRS duration from 12 lead surface ECGs and ventricular 
function assessed by transthoracic echocardiography. Deaths were identified from the hospital 
database, automatically updated by the Office for National Statistics, which registers all UK 
deaths.  
Preoperative CPEX testing was performed using a symptom-limited graded treadmill exercise. 
Peak oxygen uptake (peak V̇O2), ratio of minute ventilation to carbon dioxide production 
(VE/VCO2) and anaerobic threshold were assessed. Tests were excluded from subsequent 
analysis if the respiratory quotient value was <1 (n=7). Heart rate reserve was calculated as peak 
pulse rate on exercise minus resting pulse rate. 
The primary outcome measure of the study was all-cause mortality. Early death was defined as 
death within 30 days of surgery. The secondary outcome measure was need for further 
pulmonary valve intervention, whether surgical or percutaneous. Follow-up was to the latest 
clinic visit. To assess the potential impact of surgical era, earlier era was defined as the period 
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between 1993 and 2004 (n=62), whereas later era was the period between 2005 and 2010 
(n=159), the latter coinciding with a marked increase in annual surgical volumes of PVR at our 
centre. 
Results are presented as mean and standard deviation if normally distributed, or median and 
interquartile range (IQR) if not normally distributed. Rank correlation analyses were used to 
investigate the association between year of surgery and baseline CPEX parameters. Log-rank 
statistic was calculated to assess the difference in survival between earlier and later era. 
Differences in discrete variables were tested with Chi-squared. Comparison of these features 
between patients that died and those surviving was also made using unpaired t-tests or Wilcoxon 
tests depending on data distribution. Kaplan-Meier curves were constructed to illustrate survival 
and freedom from events and Log rank P-values are provided. The correlation between 
preoperative parameters of CPEX and early surgical (30 days) mortality was tested using uni- 
and multivariable logistic regression analyses. Cox proportional-hazards analysis was used to 
assess the association between variables and all-cause mortality. A two-sided P-value <0.05 was 
considered significant. 
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RESULTS 
Patient characteristics 
Patient characteristics are summarised in Table 1. Between 1993 and 2010, 221 surgical 
PVRs were performed in 220 adults with rTOF. Median age at PVR was 32 (25 – 40) years. 
Twelve patients (6%) had a previous pulmonary valve implant, including 2 patients who had a 
conduit type of rTOF.  Fifty-six percent of patients were symptomatic with exertional dyspnoea 
and or fatigue, 21% with clinical arrhythmia, 60% were in New York Heart Association class II, 
III or IV, 25% were medicated with regular diuretics and 5% has signs or symptoms of heart 
failure (Table 1).  Four (2%) operations were for acute endocarditis refractory to medical 
therapy, requiring urgent surgery. An additional 3 (1%) patients had endocarditis which, 
although medically treated, resulted in valve degeneration requiring subsequent PVR. 
Pulmonary valve replacement surgical characteristics 
The number of patients undergoing surgical PVR at our centre increased exponentially 
during the study (Figure 1). This increase was more pronounced from 2005 onwards. Thirty-four 
patients (15%) had undergone multiple (≥2) previous sternotomies at the time of index PVR. A 
homograft was used in 117 cases (63 pulmonary, 45 aortic, 9 unknown), stented xenograft in 
103, and a mechanical prosthesis in 1 patient (Table 2). The rates of xenograft use increased 
over time (Figure 1). Other right ventricular (RV) interventions at the time of PVR included 
revision of RV outflow tract including patching (40%), pulmonary artery patching (29%), RV 
muscle resection (11%), and RV plication (19%). Two patients had had complications from 
previous percutaneous pulmonary valve implantations (one failed deployment at initial 
procedure, the other developed valve failure with progressive regurgitation following incomplete 
medical treatment of fungal endocarditis); both underwent surgical percutaneous pulmonary 
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valve explantation combined with surgical PVR. Thirty-six percent of cases involved additional 
surgery including tricuspid valve repair (13%), branch pulmonary artery augmentation (12%) 
and residual ventricular septal defect closure (9%). Surgical details including choice of 
prosthesis and concomitant lesions requiring treatment are summarised in Table 2. The length of 
hospital stay was 7 (6-10) days.  
Mortality 
Thirty-day (early) mortality was 2.3%, due to severe RV failure in all 5 cases. 
Characteristics of patients who died are summarised in Table 3. Overall survival was 97% at one 
year (95% confidence interval [CI] 95-99%), 96% at 3 years (95% CI 93-99%) and 92% at 10 
years (95% CI 89-97%). Cardiac causes accounted for 8 out of 9 late deaths. Five out of 8 were 
due to heart failure of which one was in the context of multiorgan failure at 37 days due to 
unrelenting sepsis despite medical and surgical treatment for the index fulminant infective 
endocarditis. Three out of 8 late deaths were arrhythmic (witnessed out of hospital cardiac 
arrests). QRS duration from the preoperative ECG was 184±28 ms in those that died (early or 
late) versus 153±22 ms in survivors (P<0.001). Previous pulmonary valve implantation (n=29), 
whether due to conduit insertion at the time of original repair or due to previous redo surgery for 
pulmonary regurgitation had no influence on mortality (Hazard ratio [HR] 0.92, CI 0.21 to 4.13; 
P=0.92). 
Preoperative cardiopulmonary exercise testing as a predictor of mortality 
Preoperative cardiopulmonary exercise testing was performed in 154 patients (70% of 
total, 79% of those operated from 2000 when preoperative CPEX was introduced) at a median of 
9 (5-16) months prior to surgery.  Preoperative peak V̇O2 was significantly lower in those 
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patients that died early; furthermore patients with a lower quartile peak V̇O2 had markedly 
increased mortality (Figure 2).  
The median preoperative peak V̇O2 was 21.5 mL/kg/min. No patient died with peak V̇O2 
> 21.5 mL/kg.min. Using a cutoff value of peak V̇O2 < 20mL/kg/min, gives 100% sensitivity and 
56% specificity for perioperative death. Early mortality for patients with preoperative peak V̇O2  
< 20mL/kg/min was 5.7% versus 0% in patients with preoperative peak V̇O2 ≥ 20mL/kg/min. 
Table 4 presents the results of the uni- and multivariate logistic regression analysis exploring the 
association between peak V̇O2 and early mortality. In a stepwise multivariate logistic regression, 
peak V̇O2 achieved was the only independent predictor of early mortality (Table 4).  
To investigate the association between these variables and early or late mortality Cox 
proportional-hazard analyses were used. These confirmed a significant association between peak 
V̇O2 (HR 0.77 [95% CI 0.63-0.94]; P=0.012), VE/VCO2-slope (HR 1.08 [95% CI 1.02-1.13]; 
P=0.006), and heart rate reserve and outcome (HR/10 bpm 0.73 [95% CI 0.55-0.97]; P=0.033). 
Clinical symptoms (NYHA >1) did not predict early mortality (HR 2.21 [95% CI 0.22-21.80]; 
P=0.47. RV function on echocardiography (RV score ≥1; at least mild RV impairment) did not 
predict early mortality (HR 1.26 [95% CI 0.11-14.15]; P=0.8). 
Earlier versus later era pulmonary valve replacement 
Baseline characteristics and cardiopulmonary exercise testing  
Earlier era patients were more commonly operated on for pulmonary stenosis or mixed 
pulmonary valve disease than isolated pulmonary regurgitation, (45% (28/62) versus 8% 
(13/159); P=0.01). Earlier era patients had a worse functional class compared with later era 
patients (NYHA class I/II/III/IV; 31/47/19/3 % versus 43/48/9/0 %, respectively; P=0.008). 
Earlier era patients were more likely to volunteer symptoms of shortness of breath and fatigue 
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than later era patients (44/56; 79% versus 79/158; 50%; P<0.001). There was no statistically 
significant difference in preoperative QRS duration between the two groups (167±26 versus 
158±27 ms; P=0.18).  Preoperative peak V̇O2 was higher in patients operated on more recently 
(ρ=0.39, P<0.001), (Figure 3). Better preoperative exercise capacity was also reflected by a 
lower VE/VCO2 slope (ρ=-0.24, P=0.003) and a greater heart rate reserve (ρ=0.31, P<0.001) in 
more recently operated patients. 
Outcome 
Hospital length of stay was shorter in later era patients compared to earlier era patients (7 
[6-9] days versus 9 [7-16] days; P<0.001). Survival following PVR in the earlier era was 94% 
(95% CI 88–100%) at 1 year, 92% (95% CI 85-99%) at 3 years and 87% (95% CI 79-96%) at 10 
years. Survival in the later era was 99% (95% CI 97-100%) at 1 year and 98% (95%CI 95-100%) 
at 3 years, which was significantly better when compared with the earlier era (P=0.019) as 
shown in Figure 4. 
Clinical follow up, longevity of pulmonary valve prostheses and need for re-intervention 
Functional class improved following PVR: at the latest follow up NYHA class was 
I/II/III/IV; 83/13/3/2 % compared to 41/48/11/1 %, preoperatively (P<0.001). Sixty percent of 
patients were in NYHA class ≥2 preoperatively compared to 18% at the latest follow-up. In 
contrast to improvement in NYHA class, there was no significant change in peak V̇O2 at a 
median follow-up of 3.0 (1.7-4.7) years from index PVR (baseline versus latest CPEX 21.6±7.5 
versus 22.2±7.5 mL/kg/min; P=0.52), nor in VE/VCO2 slope (36.4±11.7 versus 33.9±10.8; 
P=0.17) or in heart rate reserve (85±28 versus 81±25 bpm; P=0.27) whenever paired 
preoperative and follow-up CPEX data were available (n=53). Similarly, QRS duration did not 
change at a median of 3 (2.3-4.6) years (baseline 156±25 versus latest ECG 155±23ms; P=0.35).  
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Freedom from moderate or severe pulmonary stenosis at transthoracic echocardiography 
was 93% (95% CI 88-98%) at 5 years whereas freedom from moderate or severe pulmonary 
regurgitation was 95% (95% CI 91-99%) at 5 years (number at risk 48, for both). Of the 5 
patients that had pulmonary valve re-intervention after index PVR, 2 underwent further surgical 
PVR, and 3 percutaneous PVR. All 5 patients had received a homograft (3 aortic, 2 pulmonary) 
at index PVR. Freedom from redo surgical or transcatheter PVR was 100% at 1 year, 98% at 5 
years (95% CI 95-100%), and 96% at 10 years (95% CI 91-100%) (Figure 5). Median follow up 
for homografts was longer than xenografts (4.3 [1.6-9.4] versus 2.4 [1.0-4.3] years). There was 
no difference in early mortality between patients undergoing homograft or xenograft 
implantation (4/121 versus 1/107; P=0.44). There was no difference in re-intervention rates 
between homografts and xenografts on Kaplan-Meier analysis (log-rank P=0.98). 
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DISCUSSION 
In our single centre cohort reflecting 17 years experience of PVR in 220 adults with 
previous rTOF, pulmonary valve surgery is a low risk endeavour with low early and late 
mortality. Preoperative peak oxygen consumption was predictive of early mortality. Furthermore 
patients undergoing PVR in the later era had a better early and mid-term outcome compared with 
those operated on in the earlier era, the former being referred for surgery while in better 
functional class and with better objective cardiopulmonary exercise capacity. 
A clear rise in the number of PVRs performed in our centre is evident from 2005 
onwards, in keeping with evolving and broadening indications for PVR in this group of patients. 
The detrimental effects of pulmonary regurgitation are now widely accepted, which, in turn, has 
led to earlier PVR, in most instances before overt symptoms and cardiovascular decompensation 
develop.  In the past, in keeping with practice at the time, patients were considered for PVR only 
for significant RV outflow tract obstruction (RV pressure 2/3 systemic) or for severe pulmonary 
regurgitation in conjunction with  arrhythmia, exercise intolerance and heart failure. With time, 
milder symptoms, new onset TR, or increasing RV size and/or deteriorating function became 
selective  indications. When the deleterious effects of pulmonary regurgitation were more fully 
appreciated circa 2000, asymptomatic patients with pulmonary regurgitation were considered for 
PVR, including patients with lower or declining peak V̇O2 , usually but not necessarily in 
conjunction with other clinical features. From circa 2005 quantified RV volumes measured with 
cardiovascular magnetic resonance were also incorporated in the decision-making. This changing 
clinical practice is concordant with recent reports.7-16 Cardiopulmonary exercise testing has 
increasingly been employed in our centre since 2000 in assessing patients and assisting the 
timing of surgical or transcatheter intervention rather than relying solely on symptoms. 
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Our data confirm that surgical PVR is a low risk operation.10, 14, 17-30 This is in spite of the 
fact that symptomatic patients and patients with multiple previous sternotomies were included in 
our report. All five patients who died early, however, died from right heart failure suggesting that 
despite our modified, proactive approach for PVR we still operate too late in some cases. Our 
series, confined to adult patients, had an overall survival of 97% at 1 year, 96 % at 3 years and 
92% at 10 years. Therrien et al. reported 92% survival at 5 years and 86% at 10 years in 70 adult 
rTOF patients after pulmonary valve surgery and early mortality of 4%.31 Discigil et al. reported 
95% survival at 5 years and 76% at 10 years in 42 adults undergoing PVR; the same group 
reported a 2% early and 14% late mortality amongst children.26 Our data suggest a drop in 
mortality in contemporary surgical PVR. This may be associated with higher volume adult 
congenital heart surgery, improved experience with redo sternotomy, improved surgical 
myocardial protection and perhaps above all evolving and better selection criteria leading to 
earlier PVR. Conversely, PVR in the earlier era was performed later in symptomatic patients 
who may have had a more advanced myocardial impairment accounting for the higher NYHA 
class and objectively worse impairment of cardiopulmonary exercise capacity. It is reasonable to 
presume that patients referred for PVR in the earlier era were at a later stage of disease 
progression. Their reduced peak oxygen uptake 32, 33or blunted heart rate reserve,34 and increased 
VE/VCO2 slope35 are all established risk factors for adverse outcome in adult congenital heart 
disease irrespective of surgery.  
Importantly, peak V̇O2 was predictive of early mortality in our study. For every 
mL/min/kg reduction in preoperative peak V̇O2 there was an approximately 30% increased risk 
of early mortality. This novel finding of a relationship between CPEX results and perioperative 
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mortality is of interest and merits further, prospective validation not only in patients undergoing 
PVR but also in other adult congenital heart disease subjects considered for redo surgery.  
Peak V̇O2, was highly sensitive to high operative risk but its limitation is lack of 
specificity. Though all patients that died had peak V̇O2<20 mL/kg/m2, a lower range result for 
peak V̇O2 was also recorded in 55% of survivors which in turn did not preclude a good outcome. 
Clinically, our data has taught us that a low peak V̇O2 may be judiciously used, in conjunction 
with other clinical data and context, as an indicator of potentially increased surgical risk; patients 
with peak V̇O2<20 mL/kg/m2 are more likely therefore to carry a higher surgical risk than the 2% 
risk reported herewith for allcomers. 
Our data show that QRS duration was prolonged in those patients that died. QRS 
prolongation is a predictor of sustained ventricular tachycardia and sudden cardiac death in 
rTOF.3 QRS duration remains a risk factor if prolonged after restoration of pulmonary 
competence.36 Mean QRS duration did not shorten significantly 3 years after PVR in our study. 
Late cardiac death was arrhythmic in 3 cases despite successful PVR (all 3 patients from the 
earlier era). This reinforces the point that hemodynamic intervention with PVR alone does not 
necessarily abort the risk of sudden cardiac death. High risk patients, for example with extensive 
fibrosis at cardiovascular magnetic resonance imaging,37, 38 may need and benefit from additional 
arrhythmia-targeting intervention and/or implantation of an automated internal cardiac 
defibrillator. 
There was an increase in the proportion of xenografts used in the course of our study. 
This may reflect limited availability of suitably sized valves and/or a change in surgical 
preference. A potential advantage of homografts over stented valves (xenografts) is better 
hemodynamics. Homografts may also provide a more suitable substrate for later percutaneous 
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pulmonary valve implantation. A perceived disadvantage of homografts is the greater risk for 
early regurgitation if the geometry of the valve is jeopardized during implantation. This may be 
true when a markedly enlarged and distorted right ventricular outflow tract is present. In the 
current study, there was no differences in the durability of homografts compared to xenografts. 
Longer follow-up data may be necessary to elucidate the potential advantages of the superior 
hemodynamics associated with homografts. There was no difference in early mortality associated 
with choice of prosthesis. 
Clearly, additional markers to current indices are required for optimal timing of PVR. CPEX 
testing may be one of them. Surgical PVR may be lower risk when cardiovascular fitness is 
maintained, justifying earlier intervention. Indeed, our data show that a better peak V̇O2 at 
baseline is associated with lower early mortality after PVR. Patients who had follow-up CPEX 
seem to have stable rather than improving exercise capacity in the medium term. This may be a 
reflection that isolated pulmonary regurgitation was the most common culprit lesion for PVR in 
our series. Others have demonstrated similar lack of improvement in peak V̇O2 following PVR 
unless pulmonary stenosis was the predominant lesion preoperatively.14, 39, 40 Heart rate reserve 
and VE/VCO2 slope also remained unchanged in our study. Thus far, RV volumes do not 
correlate well with peak V̇O2 in pulmonary regurgitation.41, 42 Despite improvement in LV filling 
and cardiac output and reduction in RV volumes after PVR 14, 28, 43 peak V̇O2 has not been found 
to improve post intervention in our study or in other studies. 14, 39, 14, 40  Pulmonary regurgitation 
may significantly limit cardiac output during exercise although other factors such as reduced 
diastolic time with increased heart rate, abnormal RV diastolic and pressure response to exercise 
due to myocardial fibrosis and or hypertrophy, and reduced pulmonary vascular resistance may 
also play a role in effective forward pulmonary blood flow.  For these reasons, peak V̇O2 may be 
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insensitive to change following restoration of pulmonary valve competence. Additionally, once 
peak V̇O2 becomes impaired irreversible RV dysfunction may already play a role. It may be that 
different responses to surgery are due to differing degrees of RV stiffness and fibrosis. Fibrosis 
may be due to factors present before repair such as cyanosis and pressure overload or as a result 
of operative technique and myocardial protection, or progressive changes with age and 
prolonged and increasing volume overloading. Further studies could explore the possibility that 
there are cutoff values of preoperative peak V̇O2 above which an improvement in peak V̇O2 
postoperatively is anticipated. Given the poor correlation between peak V̇O2 and RV volume 
increase due to pulmonary regurgitation 41, 42 such cutoff values in a future larger study may or 
may not relate to those so far suggested for RV recovery as measured by reduction in RV 
volumes measured with cardiovascular magnetic resonance (CMR). We propose therefore, that 
PVR may still be considered too late even with our current proactive approach to generate 
significant improvement in exercise capacity. Earlier intervention, in the presence of a more 
compliant RV with preserved RV function, may lead to improved exercise performance but this 
clearly needs to be validated in future studies. Peak V̇O2 is a composite measure of integrated 
cardiovascular and respiratory function and may also reflect physical conditioning and other co-
morbidity. Not all these aspects will necessarily be improved with hemodynamic intervention 
alone but, nevertheless contribute to surgical risk.  
Freedom from surgical or transcatheter pulmonary valve reimplantation in our adult 
series was reassuring at 100% at 1 year, 98% at 5 years and 96% at 10 years. Freedom from redo 
homograft replacement was 91% at 5 years and 84% at 10 years in the Oosterhof et al., study of 
116 rTOF patients,17 and freedom from redo PVR 75% at 10 years in the study of 170 adults and 
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children by Lee et al.,16suggesting an improving trend of lesser need for re-intervention in our 
series. 
While we advocate earlier PVR, this approach may not be without potential problems. 
Younger age at pulmonary valve replacement may be associated with a higher rate of valve 
failure and early reoperation44, 45  though this should be less of an issue in adult patients where 
somatic growth is not a concern. Operating earlier on the assumption that next valve 
implantation can be performed percutaneously carries an additional appeal but some patients 
may not be suitable for this evolving technique in future. Hence, longevity of pulmonary valve 
prostheses remains a concern with respect to timing of surgical pulmonary valve implantation. 
Limitations 
Our data are limited by the retrospective study design. Although 70% of patients had 
preoperative CPEX testing, paired pre- and post-operative CPEX data were only available in 
24% (53 patients). Though there was clear value in preoperative peak V̇O2 in evaluating 
mortality risk, low peak V̇O2 was highly sensitive but not specific and causality cannot be 
assumed. Furthermore, the indications for PVR evolved with time during the study period and 
were individualised to patients rather than adhered to a protocol. Nevertheless, we report the 
largest (n=221), single centre, unselected clinical series with a complete data set on early and late 
mortality and on the need for re-intervention. 
Outcomes from our tertiary centre with high volume care of congenital heart disease 
cannot necessarily be extrapolated to other settings. We believe, however, our group of patients 
to be representative of contemporary tertiary practice. 
Imaging data with CMR derived ventricular volumes were not routinely acquired for all 
patients. This is because of the relatively long period of observation without exclusions dating 
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back to 1993 and the lack of defined CMR cut-offs for pulmonary regurgitation at the time to 
guide surgery. Cut-off values suggesting RV end-diastolic volume 150-160mL/m2 or end systolic 
volume >80-90mL/m2 were not proposed until 200511 to 2008 13,14 and they continue to 
evolve.15,16 Furthermore, many patients herewith did not undergo clinical CMR for quantification 
of volumes, particularly so in the earlier surgical era (n=8, only). Further data, including the 
degree of postoperative RV volume change, however, are the subject of ongoing prospective 
studies. 
CONCLUSIONS 
Pulmonary valve replacement has a low and improving mortality, with low 10-year re-
intervention rates. Patients operated more recently in our cohort were less symptomatic and had 
better exercise capacity at the time of referral for surgical PVR compared to those operated in the 
earlier part of the study, reflecting recent trends towards earlier PVR. This trend of earlier PVR 
was associated with lower mortality. Furthermore, preoperative peak oxygen uptake was 
predictive of early postoperative mortality, reinforcing the value of CPEX in this patient group.  
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TABLES 
Table 1. 
Characteristics of 220 repaired tetralogy of Fallot patients undergoing 221 pulmonary 
valve replacements at the Royal Brompton Hospital between 1993 and 2010 
Parameter* N=220
  
Male, n (%) 128 (58) 
  
Age at PVR, years 32.0 (25.0-40.0) 
  
Age at palliative surgery, years 2.7±4.2 
  
TOF with associated lesions 20 
      - pulmonary atresia 11 
      - absent pulmonary valve 5 
      - atrioventricular septal defect 2 
      - absent left pulmonary artery 1 
      - partial anomalous pulmonary venous return 1 
  
Previous Palliative Operation, n (%) 74 (34) 
 - Blalock-Taussig Shunt 43 
 - Waterston shunt 20 
 - Potts shunt 1 
 - Central shunt 2 
 - Brock procedure 5 
 - Open pulmonary valvotomy 2 
  
Nature of repair (n=210), n (%)  
     -Use of conduit 19 (9) 
     -Use of RVOT patch 57 (27) 
     -Use of transannular patch 108 (51) 
  
Number of sternotomies prior to PVR (1/2/3)† 187/31/3 
  
Previous pulmonary valve replacement, n (%) 12 (5) 
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Abbreviations: AT; atrial tachycardia, AF; atrial fibrillation, AV block; atrioventricular conduction block, LV; left ventricle, 
NYHA; New York Heart Association, PPM; permanent pacemaker, RV; right ventricle, RVOT; right ventricular outflow tract, 
TOF; tetralogy of Fallot, VT; ventricular tachycardia (sustained ≥30 second duration, syncopal or presyncopal) 
*Data are presented as median (interquartile range) or mean±standard deviation. Percentages are rounded to the nearest whole 
integer, † For all 221 operations, ‡ Subsets not mutually exclusive 
§Echocardiographic grade 1=good, 2=mildly impaired, 3=moderately impaired, 4=severely impaired. 
 
  
  
Preoperative clinical status  
PVR  for predominant regurgitation/stenosis/both, n 178/36/7 
  
Symptoms ‡   
-NYHA class I/II/III/IV, % 41/48/11/1 
-diuretic use, % 25 
-signs and symptoms of decompensated heart failure, % 5 
-patient reported shortness of breath on exertion/ fatigue % 56 
 
Arrhythmia (VT/ established AF/AT/PPM for AV Block‡), % 21 (12/6/25/8) 
-syncope (confirmed VT/AT/undocumented arrhythmia), % 10 (45/18/36) 
  
Electrocardiogram  
-QRS duration, mean in ms 156±25 
  
Preoperative cardiopulmonary exercise testing, n=154  
- Peak V̇O2, mL/kg/min 23±8 
- % predicted peak V̇O2 65±18 
-Peak V̇O2 ≤70% predicted,  % 38 
  
Echocardiography, n=159  
-LV function grade 1/2/3/4, % § 87/11/1/2 
-RV function grade 1/2/3/4, % § 17/50/28/5 
-More than mild TR, % 11 
  
Preoperative CMR  
-RV end diastolic volume index, mL/m2, n=99 156±45 
-RV end systolic volume index, mL/m2, n=99 87±34 
-RV:LV end diastolic volume ratio, n=130 2.1:1 
-RV ejection fraction, %, n=132 45±9 
-Pulmonary regurgitant fraction, %, n=136 39±12 
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Table 2. 
Pulmonary valve surgical characteristics of 220 repaired tetralogy of Fallot patients 
undergoing 221 pulmonary valve replacements at the Royal Brompton Hospital between 
1993 and 2010 
Parameter 
  
Beating heart procedures, n (%) 99 (45) 
Bypass time, minutes 113 ± 59 
Cross clamp time, minutes 42 ± 45 
Temperature, °C 30.9 ± 3.1 
  
Homografts, n (%) 117 (53) 
Homograft size, mm (median/ interquartile range/ range) 24 / 23-25 / 15-28  
Xenografts 103 (47) 
Porcine, n (%) 72 (70) 
Mosaic, n (%) 49 (48) 
Hancock, n (%) 20 (19) 
Unspecified, n (%) 1 (1) 
Matrix P xenograft, n (%) 1 (1) 
Freestyle porcine aortic 1 (1) 
Bovine pericardial, n (%)  31 (30) 
Carpentier-Edwards Perimount, n (%) 28 (27) 
Mitroflow, n (%) 3 (3) 
Xenograft size, mm (median/ interquartile range/ range) 25 / 25-27 / 23-29  
  
Additional surgical procedures,  n (%)* 76 (36) 
Branch pulmonary artery augmentation, n (%) 26 (12) 
Pulmonary artery patch, n (%) 61 (29) 
Right ventricular outflow tract patch, n (%) 84 (40) 
Right ventricular outflow tract muscle resection, n (%) 24 (11) 
Right ventricular outflow tract plication, n (%) 40 (19) 
Residual ventricular septal defect closure, n (%) 18 (9) 
Tricuspid valve surgery  
-Tricuspid ring annuloplasty, n 10  
-Tricuspid annuloplasty ring size, mm (median/ interquartile range) 32mm/ 31-33 
Atrial septal defect or patent foramen ovale closure, n (%) 6 (3) 
Aortic root intervention, n (%) 1 (1) 
Aortic valve replacement, n (%) 1 (1 ) 
Coronary surgery, n (%) 4 (2) 
Surgical ablation procedures, n (%) 5 (2) 
Other surgical procedures†, n (%) 12 (5) 
  
Length of hospital stay, days 7 (6–10) 
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* the subsets listed are not  mutually exclusive, † additional procedures including right coronary artery fistula repair, 
right coronary artery repair, removal of thrombus from branch pulmonary artery, suture of aortic  cusp perforation 
from previous endocarditis, pericardectomy, fenestration of ventricular septal defect, right atrial plication and left 
atrioventricular valve repair. 
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Table 3.  
Details of early and late mortality following PVR (total deaths,n=14) amongst 220 adult patients with previously repaired 
tetralogy of Fallot undergoing 221 pulmonary valve replacements at the Royal Brompton Hospital (1993 and 2010)  
Death Year of 
Surgery 
Age at 
surgery, 
years 
Additional surgical procedures Timing of 
death in 
relation to 
index PVR 
 
Cause of Death Documented 
Arrhythmia 
QRSd, ms 
Early(<30 day)        
10 2000 54.8 TV annuloplasty 2 days Heart Failure A Flutter/AF 179 
 2004 34.9   5 days Heart Failure No paced 
14 2004 30.9 Repair aortic root rupture and false aneurysm 4 days Heart Failure* No 111 
16 2006 36.5  3 days Heart Failure No 157 
17 2007 42.9 RA plication 3 days Heart Failure Established AF 150 
        
Late (>30 day)        
1 1993 21.5   12.6 years Arrhythmia† Syncope 165 
2 1995 42.0 TV valve repair 10.3 years Arrhythmia† Atrial fib/flutter 184 
4 1996 26.8 previous conduit 3.7 years Heart Failure AF  
5 1997 40.8 previous conduit 4.3 years Heart Failure AF 200 
6 1998 24.1 previous conduit, IE 0.1 years Heart Failure*‡ No  
8 1998 23.8 previous conduit 2.7 years Heart Failure AF 178 
7 1999 46.1 CABG SVGs to LAD and RCA  13.4 years Heart Failure VT with ICD in situ 180 
9 1999 39.3  3.6 years Perforated gallbladder AF 200 
 2007 34.1  1.6 years Arrhythmia† No 206 
        
Abbreviations: AF; atrial fibrillation, A Flutter; atrial flutter, ASD; atrial septal defect, CABG; coronary artery bypass graft, Fib; fibrillation ICD; implantable 
cardio-defibrillator, IE; infective endocarditis, LAD; left anterior diagonal, PA; pulmonary artery RA; right atrium, RCA; right coronary artery, TOF; tetralogy of 
Fallot, TV; tricuspid valve, VSD; ventricular septal defect, VT; ventricular tachycardia 
* Urgent surgery involving pulmonary valve implantation was required in these 2 patients. † All patients had witnessed cardiac arrest ‡ Patient 
died from heart and multiorgan failure related to uncontrolled endocarditis and septicaemia
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Table 4.  
Association between early deaths after pulmonary valve replacement and parameters of 
cardiopulmonary exercise testing on logistic regression analysis. 
 
Variable Odds ratio 
95%  Confidence 
Interval P-Value c-statistic, %
     
Univariate     
Peak V̇O2, mL/min/kg 0.76 0.60–0.95 0.015 85 
VE/VCO2 slope 1.09 1.02-1.17 0.009 89 
Heart rate reserve, bpm 0.97 0.94-1.00 0.041 68 
Age at index PVR, years 1.06 0.98-1.16 0.15 69 
     
Multivariate*     
Peak V̇O2, mL·min−1·kg−1 0.65 0.58-0.93 0.041 86 
*The 3 significant univariate predictors including peak V̇O2 were used in the multivariate model. 
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FIGURES 
Figure 1. Royal Brompton Hospital surgical pulmonary valve replacements in adult 
patients with repaired tetralogy of Fallot between 1993 and 2010 
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Figure 3. Change in baseline (preoperative) peak V̇O2 in adult patients with repaired 
tetralogy of Fallot referred for surgical pulmonary valve replacement over time 
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Figure 4. Survival after surgical pulmonary valve replacement in adult patients with repaired tetralogy of Fallot. A: Overall, 
total cohort; B: Earlier versus later surgical era. 
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Figure 5. Freedom from surgical or transcatheter re-intervention following surgical 
pulmonary valve replacement in adult patients with repaired tetralogy of Fallot. FU 
indicates follow-up. 
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Clinical commentary  
 
Pulmonary regurgitation is common in adult patients with tetralogy of Fallot predisposing to 
right ventricular dilatation, ventricular dysfunction, exercise intolerance, life-threatening 
arrhythmia and sudden cardiac death. Implantation of a competent pulmonary valve is 
increasingly undertaken to mitigate such adverse clinical outcome. In this single centre surgical 
series of 221 consecutive pulmonary valve replacement (PVR) operations in adults spanning a 17 
year period (1993-2010), we report low and improving early and late mortality rates. 
Cardiopulmonary exercise (CPEX) testing is increasingly employed as part of routine medical 
surveillance in these patients. More recently, impaired or deteriorating peak oxygen consumption 
during exercise (peak V̇O2) may be used as an indication to expedite PVR, before the onset of 
symptoms which are volunteered late. Our data suggest that impaired peak V̇O2 preceding PVR 
was predictive of early perioperative mortality (5.7% when peak V̇O2 <20mL/kg/min versus 0% 
when peak V̇O2 ≥20mL/kg/min). This cutoff value of 20mL/kg/min (100% sensitivity, 56% 
specificity) may therefore be used as a risk stratifier for perioperative issues. Thus, preoperative 
CPEX data may assist clinical decision-making regarding timing of surgical PVR. Operating 
earlier whilst preoperative peak V̇O2 remains relatively preserved enables patients to undergo 
surgery with lower perioperative surgical risk, an advantage to be balanced with the finite 
longevity of currently available interventions.  
 
